Urine metabolomics can discriminate between NSCLC or SCLC

<bold>Introduction:</bold> Metabolomics has the potential to aid in the typing of lung cancer (LC) which, when applied to urine, could be a non-invasive method that could improve clinical decision-making. We assessed if urine metabolomics could identify potential biomarkers that could be linked to non-small cell LC (NSCLC) and small cell LC (SCLC). <bold>Methods:</bold> 106 samples (NSCLC=97; SCLC=9) were analysed using flow infusion electrospray ion mass spectrometry (FIE-MS). The derived data were assessed by partial least squares discriminant analysis (PLS-DA) and the receiver operating characteristic (ROC) curve tests in R. <bold>Results:</bold> PLS-DA of the urine metabolomes showed the separation of NSCLC and SCLC (Figure 1A). Key metabolite differences included a steroid, a vitamin D derivative, and lipids with > 0.8 AUC values (Figure 1B). These metabolite classes have already been linked to oncogenesis. <bold>Conclusion:</bold> Our study shows that a urine-based test has the potential to aid in NSCLC vs SCLC typing of lung cancer as a novel diagnostic method. <fig><object-id>erj;64/suppl_68/PA1538/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>